1. There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment (NAT). 2. There is no significant differences in R0 rate, 5-year overall survival and recurrence-free survival between the PV/SMV preservation (PVP) group and PV/SMV resection (PVR) group. 3. PVP group showed significantly better 5-year PV/SMV stenosis free survival than the PVR group. 4. We propose that if dissection is possible and there is a high likelihood of achieving R0 resection after NAT, routine PVR may be unnecessary in PDAC patients with venous involvement.
Study Type
OBSERVATIONAL
Enrollment
264
portal/superior vein resection
5-year overall survival
from diagnosis to any cause of death
Time frame: assessed up to 60months
5-year portal/superior mesenteric vein stenosis free survival
from surgery to stenosis
Time frame: assessed up to 60months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.